Press Releases

20 Jun 2018.
MedReleaf Corp. ("MedReleaf" or the "Company") (TSX: LEAF), today announced that the Company has been granted an interim order from the Ontario Superior Court of Justice (Commercial List) authorizing various matters, including the holding of a special meeting of MedReleaf shareholders to consider the previously announced arrangement (the "Arrangement") between MedReleaf and Aurora Cannabis Inc. ("Aurora") and the mailing of a management information circular (the "Circular") in respect of the previously announced transaction whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf (the "Transaction"). As described in the Circular, MedReleaf will be seeking shareholder approval for the Arrangement under the Business Corporations Act (Ontario) (the "Arrangement Resolution").  The special meeting of MedReleaf shareholders to consider the Arrangement Resolution will be held on Wednesday, July 18, 2018 at 1:00 p.m. (Toronto time) at the offices of ...
19 Jun 2018.
Record sales and grams sold while reducing cash cost per adjusted total gram sold MARKHAM, ON , June 19, 2018 /CNW/ - MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), today announced financial and operating results for the fourth quarter and year end fiscal 2018 ending March 31, 2018 . All amounts expressed are in Canadian dollars unless otherwise noted. "In fiscal 2018 we set new records for sales and volume, introduced brands for the adult-use market, expanded our international presence, commercialized new proprietary cannabis varieties, more than doubled our production capacity and MedReleaf was named Top Licensed Producer at the 2017 Canadian Cannabis Awards," said Neil Closner , CEO of MedReleaf . "I'm immensely proud of our achievements to build a reputable, respected, and enduring business founded on integrity, high quality and strong execution, and I am confident MedReleaf will bring tremendous value to Aurora, as we combine to create a preeminent global cannabis ...
29 May 2018.
Exclusive agreement to conduct clinical research to advance the development of MedReleaf's cannabinoid health and drug products MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") and BioPharma Services Inc. (BioPharma) today announced they have entered into an exclusive agreement to conduct clinical research for cannabis and cannabis derived products. Under the agreement BioPharma will become an extension of MedReleaf's clinic development team. BioPharma will provide medical, clinical, pharmacological and lab expertise to expedite MedReleaf's product strategy to support in-market products as well as products under development for registration in Canadian and international markets. BioPharma is well positioned to accelerate MedReleaf's product development and clinical research programs through their international experience in running early phase clinical trials. MedReleaf and BioPharma will jointly provide scientific and regulatory guidance to clinical research studies ...
24 May 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), today announced it will collaborate with the Canadian Football League Alumni Association ("CFLAA") in conducting an observational study on the benefits of medical cannabis in treating chronic pain and related ailments in retired professional athletes. MedReleaf and the CFLAA recognize the opportunity to collaborate on this important study which will bring greater awareness to the potential health benefits of using medical cannabis in the treatment of ailments that include chronic pain. The joint observational study is scheduled to begin in the summer of 2018 with volunteer CFLAA member participants. "We are excited to collaborate with the CFL Alumni Association on this significant observational study with legends in the Canadian athletic arena," said Neil Closner, MedReleaf CEO. "Through ongoing research, our understanding of the benefits of medical cannabis has grown significantly and we welcome the opportunity to apply our ...
3 May 2018.
MedReleaf Corp. (" MedReleaf " or the " Company ") (TSX: LEAF) is aware of a recent news article speculating as to a potential transaction involving Aurora Cannabis . As a general policy, MedReleaf does not publicly comment on unusual market activity, rumors or speculation in the marketplace or any potential transaction unless, and until, a binding legal agreement to effect that transaction has been signed. In response to a request by Investment Industry Regulatory Organization of Canada, the Company confirms that it engages from time to time in discussions with other industry players, including Aurora Cannabis, regarding various alternatives. The Company has not entered into an agreement to effect any particular transaction, and there can be no assurance that such discussions will result in any such agreement. About MedReleaf Corp . Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational ...
27 Apr 2018.
  MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's  first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into a memorandum of understanding (MoU) with Niagara College to foster the development of cannabis production expertise in Canada through its Graduate Certificate program in Commercial Cannabis Production – Canada's first postsecondary credential in this emerging field. By partnering with Niagara College, MedReleaf is proud to be offering financial support for students and to be sharing its expertise to help develop the program's structure and curriculum in order to advance the development of the Canadian cannabis industry through a variety of activities that include: Ongoing development of the Commercial Cannabis Production program and idea generation for any new Niagara College programs or educational seminars that may evolve with the cannabis industry; Offering entrance scholarships for students who ...
16 Apr 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of Product Identification Numbers, or "PINs", for 57 of its unique medical cannabis products including dried flower, oils and capsules.  With this announcement, MedReleaf continues to demonstrate leadership among Canadian licensed producers to facilitate the coverage of medical cannabis on employer-sponsored benefits plans. Product Identification Numbers (PINs) are similar to traditional Drug Identification Numbers (DINs), designed to make it easier for employers and payers to classify and incorporate pharmaceutical and health care products into benefits coverage plans. "Medical cannabis is being covered by an ever-increasing number of employers across Canada through health spending accounts and extended health benefits plans, but without an identification number for each product, it can be difficult to incorporate and ...
12 Apr 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has closed its previously announced agreement to acquire 1 million square feet of existing greenhouse infrastructure on a 69 acre property in Exeter, Ontario ("Exeter Facility") and 95 acres of adjacent land. The total purchase price for the transaction is approximately $26 million , consisting of $21.5 million in cash and 225,083 common shares of MedReleaf . "MedReleaf is advancing on all fronts through focused capacity expansion, innovative brand and product development, and significant supply agreements that reinforce our position as one of the leading producers of premium cannabis to the Canadian adult-use and global medical markets," said Neil Closner, CEO of MedReleaf. "The Exeter Facility expansion will add timely capacity to support market share leadership in our target segments while maximizing long-term return on ...
11 Apr 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has completed a supply agreement with Société des alcools du Québec ("SAQ") to supply the future Société québécoise du cannabis (SQDC) with high quality adult recreational-use cannabis products in accordance with the previously announced Letter of Intent ("LOI"). Under the terms of the agreement, MedReleaf is committed to supplying the Quebec market with 8,000 kilograms of cannabis products per year with a minimum three-year term. "The adult-use market is rapidly approaching and since signing our LOI in February we have achieved several milestones to advance MedReleaf's position as Canada's leading premium cannabis producer," said Neil Closner , CEO of MedReleaf . "Our recently announced greenhouse acquisition in Exeter, Ontario brings MedReleaf's fully funded annual production capacity to 140,000 kilograms of cannabis products." ...
6 Apr 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the appointments of Umar Syed as Senior Vice President of Corporate Development and Andy Duncan as Vice President of Engineering. In addition to these appointments, Eitan Popper has stepped down from his position as President of MedReleaf , effective immediately. These senior leadership team changes add depth and experience from the pharmaceutical industry as part of MedReleaf's global strategy. Mr. Syed brings over 27 years of experience in the healthcare and pharmaceutical industry and was most recently at Pharmascience Inc., among Canada's largest pharmaceutical companies with distribution in over 60 countries. Mr. Duncan has over 20 years of engineering and infrastructure development experience primarily at Apotex Inc. , Canada's largest generic pharmaceutical company with a global operation and exports to over 115 countries. "As ...
3 Apr 2018.
AltaVie by MedReleaf aims to help make mindfulness more attainable MedReleaf Corp. (TSX:LEAF) Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of AltaVie by MedReleaf, the Company's premium recreational cannabis brand designed for a premium consumer who is curious, discerning about life in general and searching for physical, mental and emotional enrichment. The AltaVie product line up will contain a robust assortment of premium offerings, putting an emphasis on strains and forms that will be equally popular with the premium consumer, those new to cannabis and those interested in the wellness category, helping each segment get more out of life. To officially launch the brand, AltaVie will host an immersive evening of mindfulness, art and living in the moment, in Toronto on April 5, 2018 . Visionary poet Cleo Wade will be in attendance, and Toronto artists including Briony Douglas, Alpo Snow , Tahsin- The Good and Enzee Creative ...
21 Mar 2018.
MedReleaf has always supported a responsible, measured approach to legalization and regulation of cannabis use in Canada and appreciate the Government’s cautious and thorough approach to legalizing and regulating the industry. Nonetheless, we have concerns with the announcement from Health Canada and the Department of Justice in their Summary of Comments Received During the Public Consultation report released on Monday the 19th of March. As a licensed producer of cannabis, our goal is to ensure consumers have access to all the facts and details necessary to make informed decisions when purchasing cannabis products. On this point, we believe Health Canada’s packaging and branding recommendations miss the mark. Defaulting to a tobacco-like regime fails to recognize fundamental differences between products, or to account for current and future variations in consumption methods, such as oils or capsules.   We believe the common-sense and true risk-based approach is to regulate ...
19 Mar 2018.
MedReleaf to become the largest supplier to Cannamedical, Germany's leading independent cannabis distributor with a network of 1,800 pharmacies MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH ("Cannamedical"), a leading medical cannabis distributor to pharmacies in Germany. MedReleaf will provide Cannamedical with monthly exports of five of its premium strain varieties significantly improving the predictability and security of drug delivery to the German market. Sales to Germany will commence promptly upon the expected receipt of MedReleaf's European Medical Agency Good Manufacturing Practices ("GMP") certification and export permit from Health Canada in the coming weeks. Germany is poised to become the largest federally regulated medical cannabis market in the ...
6 Mar 2018.
MedReleaf Corp. (TSX:LEAF), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced it has entered into an exclusive licencing agreement with Woodstock Cannabis Company for use of the iconic Woodstock brand in the Canadian cannabis market. Under the terms of the agreement, MedReleaf will grow and sell a variety of strains and formats under the Woodstock banner, expanding the offering of products as regulations allow. "As a trusted symbol of the values and lifestyles of the Cannabis Community, the authenticity of Woodstock resonates with a wide segment of the population like no other brand," says Michael Lang, a principal of Woodstock Cannabis Company and one of the producers of the original Woodstock Festival.  "We chose to partner with MedReleaf because we are so impressed with their in-depth understanding of the Canadian consumer, with their unparalleled track record of producing award-winning cannabis and with their commitment to innovation.  ...
26 Feb 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into agreements to acquire 1 million square feet of existing greenhouse infrastructure on a 69 acre property in Exeter, Ontario ("Exeter Facility") and 95 acres of adjacent land for $21.5 million in cash and 225,083 common shares of MedReleaf (the "Agreements"). The existing Exeter Facility, after retrofitting, will have production capacity of up to 105,000 kilograms of cannabis product annually with a first harvest anticipated by the end of 2018, subject to receipt of a licence from Health Canada . The Exeter Facility will add large scale, low cost greenhouse production alongside MedReleaf's two Ontario -based premium indoor production facilities in Markham and Bradford , and, when fully operational, will increase the Company's fully funded capacity to approximately 140,000 kilograms of cannabis product per year. In ...
14 Feb 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has signed a Letter of Intent ("LOI") with Société des alcools du Québec ("SAQ") to supply the Province of Quebec with a guaranteed volume of high quality adult recreational-use cannabis. Under the terms of the LOI, MedReleaf will supply the Quebec market with a minimum of 8,000 kilograms of cannabis products per year. "We are proud to be working with SAQ, one of the largest purchasers of alcohol in the world, to ensure the safe, reliable, and responsible distribution of adult-used cannabis," said Neil Closner , CEO of MedReleaf . "Our capacity expansion in Bradford is on track, and we look forward to delivering an assortment of our award-winning cannabis products and brands to the Province of Quebec in the first year of this agreement." As Canada's leading supplier of premium medical cannabis, MedReleaf is recognized for its ...
13 Feb 2018.
MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the third quarter fiscal 2018 ending December 31, 2017 . All amounts expressed are in Canadian dollars unless otherwise noted. "In the third quarter, we set new records for total sales and grams sold demonstrating the strength of our underlying business while we continue to make investments in preparation for the recreational market and for international expansion," said Neil Closner, CEO of MedReleaf. "These investments are starting to bear fruit and we now have boots on the ground in six different countries working on various initiatives – both for cultivation and export. We also launched our first adult recreational-use brand, San Rafael '71, which is getting good reception from the various Provincial purchase authorities. With a strong balance sheet bolstered by $192.5 million in equity capital ...
9 Feb 2018.
MedReleaf Corp. (TSX:LEAF) Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of its first adult-use recreational brand: San Rafael '71, inspired by and designed to celebrate the spirit of classic cannabis culture. San Rafael '71 has been designed with the classic consumer in mind, one of the largest segments of the Canadian cannabis market. San Rafael '71 is for adults who are discerning and knowledgeable about cannabis products and those who value quality and an authentic experience. To mark the launch and to introduce Canada to the brand, the company has partnered with one of Canada's most well-regarded brewers, Amsterdam Brewing, to develop and launch the first San Rafael '71 product, 4:20 Pale Ale. "While cannabis aficionados eagerly anticipate the day they can buy legal products, we thought we'd offer the San Rafael '71 4:20 Pale Ale for them to enjoy while they wait," noted Darren Karasiuk , VP Strategy at MedReleaf . " ...
6 Feb 2018.
  MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has received Health Canada approval for the sale of its cannabis oil softgel capsules, becoming the first licensed producer ("LP") to bring colour-coded and cannabis variety-specific softgel capsules to market and the only LP to manufacture softgel capsules from a certified ISO and GMP facility. "Orally ingested softgel capsules give prescribing physicians and patients precise dosing in a familiar and convenient medicinal form factor. These products provide access to cannabis for an under-served patient community more comfortable taking their medication in a traditional capsule rather than by oil or through vapourizers," said Robert Gora, Senior Director of Physician Outreach. "As part of MedReleaf's ongoing focus on patient safety, our softgel capsules are uniquely colour-coded to allow patients to easily differentiate ...
31 Jan 2018.
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES ./ MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") is pleased to announce that it has closed its previously announced offering (the "Offering"), on a "bought deal" basis, pursuant to a short form prospectus, of an aggregate of 5,000,000 units of the Company ("Units") at a price of $26.50 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of $132,500,000. Each Unit consisted of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each full Common Share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $34.50 (subject to adjustment in certain circumstances) until January 31 st , 2020. In addition, in the event that the volume weighted average trading price of ...
29 Jan 2018.
MedReleaf Corp. (TSX: LEAF), North America's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today announced that it will hold a conference call to discuss its third quarter fiscal 2018 results on Tuesday, February 13, 2018 at 8:00 a.m. (ET) . The call will be hosted by Neil Closner , Chief Executive Officer, and Igor Gimelshtein , Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call. Third Quarter Fiscal 2018 Conference Call Details: Date: Tuesday, February 13, 2018 Time: 8:00 a.m. (ET) Dial in number: (647) 427-7450 or 1-888-231-8191 Live webcast: http://bit.ly/2DQpYSM Webcast will be archived for 90 days Replay: 1-855-859-2056 Available until February 20, 2018 Replay passcode: 2397185 About MedReleaf Corp. MedReleaf sets The Medical Grade Standard ™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in ...
9 Jan 2018.
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES ./ MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") announced today that it has entered into a revised agreement with a syndicate of underwriters co-led by Canaccord Genuity Corp. and GMP Securities L.P. (together the "Co-Lead Underwriters" and, collectively with the syndicate, the "Underwriters"), pursuant to which the Underwriters will purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 5,000,000 units (the "Units") of the Company at a price of $26.50 per Unit (the "Offering Price") for aggregate gross proceeds of $132,500,000 (the "Offering"). Each Unit will consist of one common share (a "Common Share") and one-half of one common share purchase warrant (each full common share purchase warrant, a "Warrant") of the Company. Each Warrant will be exercisable ...
9 Jan 2018.
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES ./ MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") announced today that it has entered into an agreement with Canaccord Genuity Corp. and GMP Securities L.P. (together the "Co-Lead Underwriters" and, collectively with the syndicate, the "Underwriters"), pursuant to which the Underwriters will purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 3,800,000 units (the "Units") of the Company at a price of $26.50 per Unit (the "Offering Price") for aggregate gross proceeds of $100.7 million (the "Offering"). Each Unit will consist of one common share (a "Common Share") and one-half of one common share purchase warrant (each full common share purchase warrant, a "Warrant") of the Company. Each Warrant will be exercisable to acquire one common share of the Company ...
4 Jan 2018.
MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today provided an update in response to the recent U.S. federal cannabis law enforcement memo issued by United States Attorney General, Jeff Sessions . The Company does not have, and does not intend to engage in, any direct, indirect or ancillary involvement in the U.S. cannabis industry until it is federally legal to do so.  As a result of MedReleaf's approach, any changes to the enforcement of United States federal laws on marijuana will not affect the Company's business. About MedReleaf Corp. MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world.  The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is an R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.  Sourced ...